Oligomerix has completed the first human safety study of OLX-07010, an oral drug designed to block the abnormal clumping of tau protein — a key driver of Alzheimer's disease. The Phase 1a trial enrolled 76 healthy adults and tested doses from 25 mg to 200 mg. Preliminary results show the drug is well-tolerated and reaches blood levels that previously reduced tau-related brain damage in animal studies. While the trial remains blinded, these early signals are encouraging. The company plans a Phase 1b study in Alzheimer's patients next, and will publish full results in peer-reviewed journals. This is an early but meaningful step toward a pill-based treatment for one of the most devastating and age-related diseases.
